Necessary Always Active
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
|
||||||
|
||||||
|
||||||
|
Developing a new drug costs, on average, more than $2.55 billion, making it critical to prove superior efficacy and safety when compared to marketed products.
In the white paper, “Unmasking the Blind of Over-Encapsulation” by Almac, the process of blinding clinical supplies through over-encapsulation is explored which is a widely accepted method that poses complex challenges requiring careful management to ensure product integrity and study accuracy.
In this white paper, you will discover:
- The role of over-encapsulation in removing patient and investigator bias while maintaining study integrity
- Key Good Manufacturing Practice (GMP) challenges and how to address them
- The importance of excipient selection, capsule shell choice, and blending for quality assurance
- Manual, semi-automated, and automated encapsulation processes, including check weighing and contamination prevention
- How placebo capsules are manufactured to maintain the blind in clinical trials
Ensure accuracy and quality in your blinded studies with Almac Clinical Services. Download the white paper today.
